-
Bai JPF, Hsu CW, 2018: Drug repurposing for Ebola virus disease: principles of consideration and the animal rule[J]. J Pharm Sci, 108, 798-806. doi: 10.1016/j.xphs.2018.09.010
-
Bixler SL, Bocan TM, Wells J, Wetzel KS, Van Tongeren SA, Dong L, Garza NL, Donnelly G, Cazares LH, Nuss J, Soloveva V, Koistinen KA, Welch L, Epstein C, Liang LF, Giesing D, Lenk R, Bavari S, Warren TK, 2017: Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus[J]. Antivir Res, 151, 97-104.
-
Brauburger K, Hume AJ, Muhlberger E, Olejnik J, 2012: Forty-five years of Marburg virus research[J]. Viruses, 4, 1878-1927. doi: 10.3390/v4101878
-
Cross RW, Mire CE, Feldmann H, Geisbert TW, 2018: Post-exposure treatments for Ebola and Marburg virus infections[J]. Nat Rev Drug Discov, 17, 413-434. doi: 10.1038/nrd.2017.251
-
Flyak AI, Ilinykh PA, Murin CD, Garron T, Shen X, Fusco ML, Hashiguchi T, Bornholdt ZA, Slaughter JC, Sapparapu G, Klages C, Ksiazek TG, Ward AB, Saphire EO, Bukreyev A, Crowe JE Jr, 2015: Mechanism of human antibody-mediated neutralization of Marburg virus[J]. Cell, 160, 893-903. doi: 10.1016/j.cell.2015.01.031
-
Flyak AI, Shen X, Murin CD, Turner HL, David JA, Fusco ML, Lampley R, Kose N, Ilinykh PA, Kuzmina N, Branchizio A, King H, Brown L, Bryan C, Davidson E, Doranz BJ, Slaughter JC, Sapparapu G, Klages C, Ksiazek TG, Saphire EO, Ward AB, Bukreyev A, Crowe JE Jr, 2016: Cross-reactive and potent neutralizing antibody responses in human survivors of natural Ebola virus infection[J]. Cell, 164, 392-405. doi: 10.1016/j.cell.2015.12.022
-
Kouznetsova J, Sun W, Martinez-Romero C, Tawa G, Shinn P, Chen CZ, Schimmer A, Sanderson P, McKew JC, Zheng W, Garcia-Sastre A, 2014: Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs[J]. Emerg Microbes Infect, 3, e84-. doi: 10.1038/emi.2014.88
-
Leffel EK, Reed DS, 2004: Marburg and Ebola viruses as aerosol threats[J]. Biosecur Bioterror, 2, 186-191. doi: 10.1089/bsp.2004.2.186
-
Madrid PB, Chopra S, Manger ID, Gilfillan L, Keepers TR, Shurtleff AC, Green CE, Iyer LV, Dilks HH, Davey RA, Kolokoltsov AA, Carrion R Jr, Patterson JL, Bavari S, Panchal RG, Warren TK, Wells JB, Moos WH, Burke RL, Tanga MJ, 2013: A systematic screen of FDA-approved drugs for inhibitors of biological threat agents[J]. PLoS ONE, 8, e60579-. doi: 10.1371/journal.pone.0060579
-
Madrid PB, Panchal RG, Warren TK, Shurtleff AC, Endsley AN, Green CE, Kolokoltsov A, Davey R, Manger ID, Gilfillan L, Bavari S, Tanga MJ, 2015: Evaluation of Ebola virus inhibitors for drug repurposing[J]. ACS Infect Dis, 1, 317-326. doi: 10.1021/acsinfecdis.5b00030
-
Marzi A, Banadyga L, Haddock E, Thomas T, Shen K, Horne EJ, Scott DP, Feldmann H, Ebihara H, 2016: A hamster model for Marburg virus infection accurately recapitulates Marburg hemorrhagic fever[J]. Sci Rep, 6, 39214-. doi: 10.1038/srep39214
-
Wang J, Cheng H, Ratia K, Varhegyi E, Hendrickson WG, Li J, Rong L, 2014: A comparative high-throughput screening protocol to identify entry inhibitors of enveloped viruses[J]. J Biomol Screen, 19, 100-107. doi: 10.1177/1087057113494405
-
Zhang L, Li Q, Liu Q, Huang W, Nie J, Wang Y, 2017: A bioluminescent imaging mouse model for Marburg virus based on a pseudovirus system[J]. Hum Vaccin Immunother, 13, 1811-1817. doi: 10.1080/21645515.2017.1325050